The Effect of Interleukin 36 Gene Therapy in the Regression of Tumor

Shiva Solahaye-Kahnamouii; Farrokh Farhadi; Mahni Rahkare-Farshi; Farzaneh Pakdel; Atabak Kashefimehr; Firouz Pouralibaba; Gholamreza Shirani; Mohammad Bayat; Abbas Karimi

International Journal of Cancer Management

The Official Journal of Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences

Outlines

Abstract
Copyright

The Effect of Interleukin 36 Gene Therapy in the Regression of Tumor

Author(s):

Shiva Solahaye-Kahnamouii¹,

Farrokh Farhadi²,

Mahni Rahkare-Farshi³,

Farzaneh Pakdel⁴,

Atabak Kashefimehr⁵,

Firouz Pouralibaba^4,*,

Gholamreza Shirani¹,

Mohammad Bayat¹,

Abbas Karimi¹

1Dept. of Oral Maxillofacial Surgery, Tehran University of Medical Science, Tehran, Iran

2Dept. of Maxillofacial Surgery, Faculty of Dentistry, Tabriz University of Medical Science, Tabriz, Iran

3Dept. of Pediatrics, Nursing and Midwifery Faculty, Tabriz University of Medical Sciences, Tabriz, Iran

4Dept. of Oral Medicine, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran

5Dept. of Periodontology, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran

International Journal of Cancer Management:Vol. 7, issue 4; e80557

Published online:Dec 31, 2014

Article type:Research Article

Received:Apr 26, 2014

Accepted:Sep 16, 2014

How to Cite:Shiva Solahaye-KahnamouiiFarrokh FarhadiMahni Rahkare-FarshiFarzaneh PakdelAtabak KashefimehrFirouz Pouralibaba Gholamreza ShiraniMohammad BayatAbbas Karimiet al.The Effect of Interleukin 36 Gene Therapy in the Regression of Tumor.Int J Cancer Manag.7(4):e80557.

Abstract

Background: Cancer immunotherapy attempts to stimulate the immune system to reject and destroy tumors and is one of the cancer treatment strategies. Recently, interluekin36 (IL36) has been used as immunotherapeutic agents in cancer gene therapy. Present study investigated that the IL36 gene therapy effects on the regression of tumor masses in mouse model. Aim of this study is determination of the gene therapy effects by IL36 in the regression of tumor masses in mouse model.

Methods: To study the therapeutic efficacy of this cytokine, WEHI-164 tumor cells were transected with mIL36 plasmids. ELISA test was used to check cytokine production by transected cells. To establish fibro sarcoma mouse model, Tumoral transfected cells were injected subcutaneously to inoculate tumor in BALB/C mice. Tumor volumes were measured by caliper. Mice were sacrificed and tumors were extracted. The expression of IL36 and IFN-γ was studied with Real-time PCR and immunoblotting. The expression of Ki-67 (a tumor proliferation marker) in tumor masses was studied by immunohistochemistry staining. In this study we had 2 groups which are treated with IL-36 and Untreated with IL-36 as a blank.

Results: The group treated with IL36 indicated decrease of tumor mass volume (p<0.001). The results of western blotting and real-time PCR showed the IL36 expression increased in the group treated with IL36 (with relative expression of 1.9).

Conclusion: Immunohistochemistry staining indicated that the Ki67expression has been reduced in the group interfered with IL36. IL36 gene therapy has therapeutic effects on the regression of tumor masses in fibro sarcoma mouse model.

Keywords

Fulltext

Full text is available in PDF.

comments